Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma.
10.1007/s00262-019-02419-4 Xu et al. Cancer Immunol. Immunother. Cited 2 times
Xu Y, Morales AJ, Cargill MJ, Towlerton AMH, Coffey DG, Warren EH, Tykodi SS
Study details